DiaMedica announces positive outcomes of ReMEDy study for AIS
Category: #health  By Saipriya Iyer  Date: 2020-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

DiaMedica announces positive outcomes of ReMEDy study for AIS

DiaMedica Therapeutics, a clinical-stage pharmaceutical firm that develops novel therapies for neurological disorders and kidney diseases, has reportedly announced positive top-line outcomes from the company’s Phase II study in AIS (acute ischemic stroke), ReMEDy. DiaMedica also released a business update and financial outcomes for three months ending on March 31, 2020. 

The company hosted a conference call with slides on May 14, 2020, at 7:00 a.m. Central Time. The call would discuss its ReMEDy top-line data, first-quarter financial outcomes and business update during this meeting. 

92 patients suffering from AIS were enrolled to treat them with the company’s candidate, DM199. Multiple plasma-based biomarkers, the Barthel Index, Modified Rankin Scale, and the National Institutes of Health Stroke Scale were the therapeutic efficacy markers for the trial. These markers were evaluated at several points across the study, which also included 90 days post-stroke.

DM199 met primary tolerability and safety endpoints and no serious adverse effects were observed in the trial. As per the top-line phase II outcomes, there was also a demonstrated therapeutic effect in patients who were given tPA (tissue plasminogen activator) before enrollment, but it was not observed in patients receiving mechanical thrombectomy.

The CEO and President of DiaMedica, Rick Pauls stated that the company is thrilled about ReMEDy’s positive top-line outcomes. These results continue to showcase DM199’s excellent safety profile and efficacy signals, consistent with the Kailikang® approval study. Kailikang is KLK1’s urine-derived form that has been used for years as a successful therapy for stroke patients in China. 

Pauls further added that these results strengthen the company’s belief that DM199 has the potential to be an important treatment for stroke victims, enhancing results while providing a substantially longer, up to 24 hours, following the onset of the stroke. The company looks forward to discussing a path to commercialize DM199 with the FDA.

 

Source credit: https://www.businesswire.com/news/home/20200513005761/en/DiaMedica-Announces-Positive-Results-Top-Line-Data-Phase



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...

Omada enters $30M acquisition deal with digital health company Physera
Omada enters $30M acquisition deal with digital health company Physera
By Saipriya Iyer

Omada Health, which has raised nearly $57 million in funding, has reportedly acquired a digital health company, Physera. It provides remote physical therapy to its customers.

The co...